APA (7th ed.) Citation

Möhler, M., & Ebert, M. (2014). Gemcitabine plus sorafenib versus gemcitabine alone in advanced biliary tract cancer: A double-blind placebo-controlled multicentre phase II AIO study with biomarker and serum programme. European journal of cancer, 50(18), . https://doi.org/10.1016/j.ejca.2014.09.013

Chicago Style (17th ed.) Citation

Möhler, Markus, and Matthias Ebert. "Gemcitabine Plus Sorafenib Versus Gemcitabine Alone in Advanced Biliary Tract Cancer: A Double-blind Placebo-controlled Multicentre Phase II AIO Study with Biomarker and Serum Programme." European Journal of Cancer 50, no. 18 (2014). https://doi.org/10.1016/j.ejca.2014.09.013.

MLA (9th ed.) Citation

Möhler, Markus, and Matthias Ebert. "Gemcitabine Plus Sorafenib Versus Gemcitabine Alone in Advanced Biliary Tract Cancer: A Double-blind Placebo-controlled Multicentre Phase II AIO Study with Biomarker and Serum Programme." European Journal of Cancer, vol. 50, no. 18, 2014, https://doi.org/10.1016/j.ejca.2014.09.013.